Scholarlink

<p>Dopamine agonists (DA) are drugs used to treat different pituitary disorders, including hyperprolactinaemia and PRL-, GH- and ACTH-secreting adenomas. The most commonly used is cabergoline. This class of drugs can induce the development of impulse control disorders (ICD) as a side effect. Currently, the prevalence and factors associated with the onset of ICD associated with DA treatment in patients with pituitary disorders are not well defined. The data available in the literature are controversial, probably due to the heterogeneity of the studies carried out in this field and the lack of standardised tools that can be used to search these side effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disturbi del controllo degli impulsi in pazienti con tumori ipofisari trattati con dopamino-agonisti

  • 期刊论文

  • 发表日期：

    2025年2月5日

查看全文
  • Giulia Cristilli,
  • Benedetta Gardini,
  • Irene Comune,
  • Martina Verrienti,
  • Maria Chiara Zatelli,
  • Maria Rosaria Ambrosio

摘要

Dopamine agonists (DA) are drugs used to treat different pituitary disorders, including hyperprolactinaemia and PRL-, GH- and ACTH-secreting adenomas. The most commonly used is cabergoline. This class of drugs can induce the development of impulse control disorders (ICD) as a side effect. Currently, the prevalence and factors associated with the onset of ICD associated with DA treatment in patients with pituitary disorders are not well defined. The data available in the literature are controversial, probably due to the heterogeneity of the studies carried out in this field and the lack of standardised tools that can be used to search these side effects.